FVIII, the blood clotting protein missing in hemophilia A, adopts multiple shapes, making it more likely to be targeted by ...

The Hemophilia B treatment landscape is entering a new era, marked by disruptive innovation, curative potential, and renewed global attention. Once viewed as a lifelong burden requiring constant ...

Researchers from the Centenary Institute have uncovered a reason why some people with hemophilia A develop resistance to ...

Genentech’s short film draws on the experiences of multiple families caring for children with hemophilia A, seeking to ...

Columnist G Shellye Horowitz argues for a new way of classifying hemophilia severity that takes both genotype and phenotype into account.

MHH haematologists successfully treat seriously ill patients with acquired haemophilia A with CAR-T cells.

Asia Pacific’s Market Growth: The Asia Pacific region is anticipated to experience significant growth in the bleeding disorder testing market, with a projected CAGR of 6.5% from 2023 to 2033. This is ...

Patients diagnosed with acquired (autoimmune) hemophilia, a serious and rare bleeding disorder, have high rates of hospital ...

Bayer’s Jivi is a factor VIII replacement therapy that has been engineered with a compound that allows for less frequent dosing. It is now indicated for patients 7 years of age and older.

VIJAYAWADA: The State government is committed to ensuring uninterrupted care for citizens with rare and chronic disorders ...

Minister emphasizes raising awareness about genetic disorders like thalassemia, sickle cell anemia, and hemophilia for timely ...

Hemophilia is a rare disorder in which the blood does not clot properly. It affects around 1 in 10,000 people, mostly males ...